The Neurobiology and Brain Tumor Program (NBTP) brings together world leading neuroscientists, cancer biologists and physicians within a highly interactive group. The overall goal of the Program is to develop curative, minimally toxic therapies, for children with brain tumors. The Program includes 30 Full Members and 4 Associate (junior mentored) Members, drawn from 9 academic departments. The members are organized into three focus groups that contribute thematic, complementary expertise to a programmatic pipeline that is translating basic neuroscience discoveries to the clinic: (i) Fundamental Neuroscience: this group studies the development, function, and death of normal and neoplastic neural tissues. The research in this group has been greatly facilitated by an NCI-P01 Program Project Grant held for over 9 years Leveraging core expertise in human and mouse genetics, this group also generates new mouse models of childhood brain tumors for biology studies and therapeutic discovery, (ii) Translational Research: this group facilitates direct collaborations between the Fundamental Neuroscience and Brain Tumor Therapy Groups, translating the results of genomic studies into robust, diagnostic tests of tumor subtype;developing new disease risk stratification tools;and employing the mouse models generated in the Program to identify potential new treatments of brain tumors, (iii) Brain Tumor Therapy: this group translates the discoveries made within groups (i) and (ii) to clinical trial. Members also study the late effects of brain tumor therapies and how to mitigate these. Clinical and laboratory-based experts work closely together to design and implement cutting-edge clinical trials that include appropriate molecular and pharmacokinetic assays. Members also play leading and collaborative roles in the national consortia, including the Children's Oncology Group and Pediatric Brain Tumor Consortium. The NBTP relies heavily upon the outstanding Shared Resources provided by the Center and close collaborative links with the other Programs. The NBTP membership is supported by $12.0 million In cancer-related funding ($7.8 million peer-reviewed;$4.2 million other sources). Program members published over 431 manuscripts during the last funding period, 28% of which were intra-programmatic collaborations and 34% of which were inter-programmatic.

Public Health Relevance

Brain tumors remain a leading cause of death among children diagnosed with cancer. There is a great need for new, less toxic treatments, since cure rates have remained static for more than a decade, and survivors suffer debilitating side effects. The NBTP, together with the unique resources and collaborations available in the Cancer Center, are working to develop effective and relatively none toxic therapies for these devastating childhood cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA021765-35
Application #
8634430
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-04-01
Project End
2019-02-28
Budget Start
2014-06-09
Budget End
2015-02-28
Support Year
35
Fiscal Year
2014
Total Cost
$305,155
Indirect Cost
$132,138
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Fernandez-Pineda, I; Ortega-Laureano, L; Wu, H et al. (2016) Guidewire Catheter Exchange in Pediatric Oncology: Indications, Postoperative Complications, and Outcomes. Pediatr Blood Cancer 63:1081-5
Zhou, Sheng; Fatima, Soghra; Ma, Zhijun et al. (2016) Evaluating the Safety of Retroviral Vectors Based on Insertional Oncogene Activation and Blocked Differentiation in Cultured Thymocytes. Mol Ther 24:1090-9
Walsh, Kyle M; Whitehead, Todd P; de Smith, Adam J et al. (2016) Common genetic variants associated with telomere length confer risk for neuroblastoma and other childhood cancers. Carcinogenesis 37:576-82
Verbist, Katherine C; Guy, Cliff S; Milasta, Sandra et al. (2016) Metabolic maintenance of cell asymmetry following division in activated T lymphocytes. Nature 532:389-93
Edginton, Andrea N; Zimmerman, Eric I; Vasilyeva, Aksana et al. (2016) Sorafenib metabolism, transport, and enterohepatic recycling: physiologically based modeling and simulation in mice. Cancer Chemother Pharmacol 77:1039-52
Paugh, Steven W; Bonten, Erik J; Evans, William E (2016) Inflammasome-mediated glucocorticoid resistance: The receptor rheostat. Mol Cell Oncol 3:e1065947
Yeh, Jennifer M; Hanmer, Janel; Ward, Zachary J et al. (2016) Chronic Conditions and Utility-Based Health-Related Quality of Life in Adult Childhood Cancer Survivors. J Natl Cancer Inst 108:
Zhao, Yunqian; Nguyen, Phuong; Ma, Jing et al. (2016) Preferential Use of Public TCR during Autoimmune Encephalomyelitis. J Immunol 196:4905-14
Interiano, Rodrigo B; Malkan, Alpin D; Loh, Amos H P et al. (2016) Initial diagnostic management of pediatric bone tumors. J Pediatr Surg 51:981-5
Snaman, Jennifer M; Kaye, Erica C; Torres, Carlos et al. (2016) Parental Grief Following the Death of a Child from Cancer: The Ongoing Odyssey. Pediatr Blood Cancer 63:1594-602

Showing the most recent 10 out of 6391 publications